TM
FDMT icon

Torren Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Torren Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,361
Closed -$17.7K – 1143
2025
Q4 		$17.7K Buy
+2,361
New +$23.9K 0.01% 615

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Torren Management's FDMT Position: Q1 2026 in Review

Torren Management sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 2,361 shares — an estimated $17.7K sold.

Torren Management first reported a position in FDMT in Q4 2025 and held it in 1 quarter. The position peaked at $17.7K in Q4 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Torren Management reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Torren Management sold 2,361 4D Molecular Therapeutics shares in Q1 2026, an estimated $17.7K.
  • Torren Management first reported a position in 4D Molecular Therapeutics in Q4 2025 and held it in 1 quarter.
  • Torren Management's 4D Molecular Therapeutics position peaked at $17.7K in Q4 2025.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.